Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia.

Westhus J, Noppeney R, Schmitz C, Flasshove M, Dührsen U, Hanoun M.

Acta Haematol. 2019 Oct 25:1-8. doi: 10.1159/000503056. [Epub ahead of print]

PMID:
31655809
2.

Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.

Lengfelder E, Görlich D, Nowak D, Spiekermann K, Haferlach C, Krug U, Kreuzer KA, Braess J, Schliemann C, Lindemann HW, Horst HA, Schiel X, Flasshove M, Hecht A, Schnittger S, Schneider S, Wörmann B, Hofmann WK, Berdel WE, Bormann E, Sauerland C, Büchner T, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Eur J Haematol. 2018 Feb;100(2):154-162. doi: 10.1111/ejh.12994. Epub 2017 Dec 4.

PMID:
29114972
3.

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.

Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, Baerlocher GM, Heim D, Hossfeld DK, Kolb HJ, Krause SW, Nerl C, Brümmendorf TH, Verbeek W, Fauser AA, Prümmer O, Neben K, Hess U, Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann WK, Müller MC, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S.

Leukemia. 2016 Jun;30(6):1255-62. doi: 10.1038/leu.2016.20. Epub 2016 Feb 9.

4.

Localized retroperitoneal Castleman's disease: a case report and review of the literature.

Aguilar-Rodriguez R, Milea SL, Demirci I, Herold S, Flasshove M, Klosterhalfen B, Kinkel H, Janßen H.

J Med Case Rep. 2014 Mar 10;8:93. doi: 10.1186/1752-1947-8-93.

5.

Myeloprotection by cytidine deaminase gene transfer in antileukemic therapy.

Lachmann N, Brennig S, Phaltane R, Flasshove M, Dilloo D, Moritz T.

Neoplasia. 2013 Mar;15(3):239-48. Review.

6.

Overdiagnosis of a typical carcinoid tumor as an adenocarcinoma of the lung: a case report and review of the literature.

Demirci I, Herold S, Kopp A, Flaßhove M, Klosterhalfen B, Janßen H.

World J Surg Oncol. 2012 Jan 23;10:19. doi: 10.1186/1477-7819-10-19. Review.

7.

Clonal inventory screens uncover monoclonality following serial transplantation of MGMT P140K-transduced stem cells and dose-intense chemotherapy.

Giordano FA, Sorg UR, Appelt JU, Lachmann N, Bleier S, Roeder I, Kleff V, Flasshove M, Zeller WJ, Allgayer H, von Kalle C, Fruehauf S, Moritz T, Laufs S.

Hum Gene Ther. 2011 Jun;22(6):697-710. doi: 10.1089/hum.2010.088. Epub 2011 Apr 11.

PMID:
21319998
8.

Gene Therapy of βc-Deficient Pulmonary Alveolar Proteinosis (βc-PAP): Studies in a Murine in vivo Model.

Kleff V, Sorg UR, Bury C, Suzuki T, Rattmann I, Jerabek-Willemsen M, Poremba C, Flasshove M, Opalka B, Trapnell B, Dirksen U, Moritz T.

Mol Ther. 2008 Apr;16(4):757-764. doi: 10.1038/mt.2008.7. Epub 2016 Dec 8.

PMID:
28178466
9.

Gene therapy of beta(c)-deficient pulmonary alveolar proteinosis (beta(c)-PAP): studies in a murine in vivo model.

Kleff V, Sorg UR, Bury C, Suzuki T, Rattmann I, Jerabek-Willemsen M, Poremba C, Flasshove M, Opalka B, Trapnell B, Dirksen U, Moritz T.

Mol Ther. 2008 Apr;16(4):757-64. doi: 10.1038/mt.2008.7. Epub 2008 Mar 4.

10.

Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.

Ebeling P, Eisele L, Schuett P, Bauer S, Schuette J, Moritz T, Seeber S, Flasshove M.

Onkologie. 2008 Feb;31(1-2):11-6. doi: 10.1159/0000111756. Epub 2008 Jan 22.

PMID:
18268394
11.

A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease.

Dürig J, Ebeling P, Grabellus F, Sorg UR, Möllmann M, Schütt P, Göthert J, Sellmann L, Seeber S, Flasshove M, Dührsen U, Moritz T.

Cancer Res. 2007 Sep 15;67(18):8653-61.

12.

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.

Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, Kreipe HH.

Blood. 2007 May 1;109(9):4106-7. No abstract available.

PMID:
17449802
13.

Reliable generation of stable high titer producer cell lines for gene therapy.

Rattmann I, Kleff V, Feldmann A, Ludwig C, Sorg UR, Opalka B, Moritz T, Flasshove M.

Intervirology. 2007;50(3):197-203. Epub 2007 Feb 2.

PMID:
17283445
14.

Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia.

Eisele L, Klein-Hitpass L, Chatzimanolis N, Opalka B, Boes T, Seeber S, Moritz T, Flasshove M.

Acta Haematol. 2007;117(1):8-15. Epub 2006 Nov 8.

PMID:
17095854
15.

Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.

Ebeling P, Bach P, Sorg U, Schneider A, Trarbach T, Dilloo D, Hanenberg H, Niesert S, Seeber S, Moritz T, Flasshove M.

J Cancer Res Clin Oncol. 2007 Mar;133(3):199-209. Epub 2006 Oct 20.

PMID:
17053889
16.

Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model.

Rattmann I, Kleff V, Sorg UR, Bardenheuer W, Brueckner A, Hilger RA, Opalka B, Seeber S, Flasshove M, Moritz T.

Blood. 2006 Nov 1;108(9):2965-71. Epub 2006 Jul 11.

PMID:
16835384
17.

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.

Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, Poser M, Mueller S, Ebeling P, Welt A, Bradwell AR, Buttkereit U, Opalka B, Flasshove M, Moritz T, Seeber S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8706-14.

18.

Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells.

Bardenheuer W, Lehmberg K, Rattmann I, Brueckner A, Schneider A, Sorg UR, Seeber S, Moritz T, Flasshove M.

Leukemia. 2005 Dec;19(12):2281-8.

PMID:
16304576
19.

Recurrent high-grade leiomyosarcoma with heterologous osteosarcomatous differentiation.

Grabellus F, Sheu SY, Schmidt B, Flasshove M, Kuhnen C, Ruchholtz S, Taeger G, Schmid KW.

Virchows Arch. 2006 Jan;448(1):85-9. Epub 2005 Oct 14.

PMID:
16228225
20.

Improving the biosafety of cell sorting by adaptation of a cell sorting system to a biosafety cabinet.

Lennartz K, Lu M, Flasshove M, Moritz T, Kirstein U.

Cytometry A. 2005 Aug;66(2):119-27.

21.

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.

Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G, Niebel W, Erhard J, Ebeling P, Zeth M, Taeger G, Seeber S, Flasshove M, Schütte J.

Int J Cancer. 2005 Nov 1;117(2):316-25.

22.

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, Müller S, Flasshove M, Moritz T, Seeber S, Nowrousian MR.

Ann Hematol. 2005 Sep;84(9):594-600. Epub 2005 Mar 3.

PMID:
15744524
23.

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, Flasshove M, Hense J, Bojko P, Metz K, Moritz T, Seeber S, Nowrousian MR.

Eur J Haematol. 2005 Jan;74(1):40-6.

PMID:
15613105
24.

[Interdisciplinary cooperation in the treatment of complex patients with advanced testicular germ cell tumor].

Heidenreich A, Krege S, Flasshove M.

Urologe A. 2004 Dec;43(12):1521-30. Review. German.

PMID:
15592709
25.

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C; European Germ Cell Cancer Consensus Group.

Ann Oncol. 2004 Sep;15(9):1377-99. Review.

PMID:
15319245
26.

Efficient protection from methotrexate toxicity and selection of transduced human hematopoietic cells following gene transfer of dihydrofolate reductase mutants.

Meisel R, Bardenheuer W, Strehblow C, Sorg UR, Elmaagacli A, Seeber S, Flasshove M, Moritz T.

Exp Hematol. 2003 Dec;31(12):1215-22.

PMID:
14662327
27.

Hematoprotection by transfer of drug-resistance genes.

Flasshove M, Moritz T, Bardenheuer W, Seeber S.

Acta Haematol. 2003;110(2-3):93-106. Review.

PMID:
14583669
28.

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.

Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, Flasshove M, Ottmann OG, Jung W, Cavalli F, Kuse R, Thomalla J, Serve H, O'Farrell AM, Jacobs M, Brega NM, Scigalla P, Hossfeld DK, Berdel WE.

Blood. 2003 Oct 15;102(8):2763-7. Epub 2003 Jul 3.

PMID:
12843001
29.

Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.

Nowrousian MR, Waschke S, Bojko P, Welt A, Schuett P, Ebeling P, Flasshove M, Moritz T, Schuette J, Seeber S.

Ann Oncol. 2003;14 Suppl 1:i29-36.

PMID:
12736228
30.

Gene therapy for sarcoma.

Fruehauf S, Veldwijk MR, Berlinghoff S, Basara N, Baum C, Flasshove M, Hegewisch-Becker S, Kröger N, Licht T, Moritz T, Hengge UR, Zeller WJ, Laufs S.

Cells Tissues Organs. 2002;172(2):133-44. Review.

PMID:
12426490
32.

Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.

Jansen M, Sorg UR, Ragg S, Flasshove M, Seeber S, Williams DA, Moritz T.

Cancer Gene Ther. 2002 Sep;9(9):737-46.

33.

Optimized retroviral transduction protocol for human progenitor cells utilizing fibronectin fragments.

Trarbach T, Greifenberg S, Bardenheuer W, Elmaagacli A, Hirche H, Flasshove M, Seeber S, Moritz T.

Cytotherapy. 2000;2(6):429-38.

PMID:
12044223
34.

Role of angiogenesis inhibitors in acute myeloid leukemia.

Fiedler W, Staib P, Kuse R, Dührsen U, Flasshove M, Cavalli F, Hossfeld DK, Berdel WE.

Cancer J. 2001 Nov-Dec;7 Suppl 3:S129-33. Review.

PMID:
11779083
35.
36.

Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia.

Flasshove M, Meusers P, Schütte J, Noppeney R, Beelen DW, Sohrab S, Roggenbuck U, Kemmeries G, Brittinger G, Seeber S, Scheulen ME.

Ann Hematol. 2000 Oct;79(10):533-42.

PMID:
11100742
37.

Type and position of promoter elements in retroviral vectors have substantial effects on the expression level of an enhanced green fluorescent protein reporter gene.

Flasshove M, Bardenheuer W, Schneider A, Hirsch G, Bach P, Bury C, Moritz T, Seeber S, Opalka B.

J Cancer Res Clin Oncol. 2000 Jul;126(7):391-9.

PMID:
10929761
38.

Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial.

Eberhardt W, Stamatis G, Stuschke M, Wilke H, Müller MR, Kolks S, Flasshove M, Schütte J, Stahl M, Schlenger L, Budach V, Greschuchna D, Stüben G, Teschler H, Sack H, Seeber S.

Br J Cancer. 1999 Dec;81(7):1206-12.

39.

Transfer of the cytidine deaminase cDNA into hematopoietic cells.

Flasshove M, Frings W, Schröder JK, Moritz T, Schütte J, Seeber S.

Leuk Res. 1999 Nov;23(11):1047-53.

PMID:
10576510
41.

Thrombopoietin serum levels at the start of mobilization, collection, and transfusion of autologous peripheral blood stem cells.

Bojko P, Nowak N, Moritz T, Flasshove M, Harstrick A, Seeber S.

J Clin Apher. 1999;14(2):57-62.

PMID:
10440940
42.

Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.

Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Müeller MR, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S.

J Clin Oncol. 1998 Feb;16(2):622-34.

PMID:
9469351
43.

Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA.

Flasshove M, Banerjee D, Leonard JP, Mineishi S, Li MX, Bertino JR, Moore MA.

Hum Gene Ther. 1998 Jan 1;9(1):63-71.

PMID:
9458243
44.

Low Density Mononuclear Cells from Umbilical Cord Blood as a Target for Retrovirally Mediated Gene Transfer.

Yurasov SV, Flasshove M, Vladimirskaya EB, Rumyantsev AG, Moore MA.

Russ J Immunol. 1996 Dec;1(1):35-40.

PMID:
12687040
45.

Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro.

Schröder JK, Kirch C, Flasshove M, Kalweit H, Seidelmann M, Hilger R, Seeber S, Schütte J.

Leukemia. 1996 Dec;10(12):1919-24.

PMID:
8946931
46.

Density enrichment and characterization of hematopoietic progenitors and stem cells from umbilical cord blood.

Yurasov SV, Flasshove M, Rafii S, Moore MA.

Bone Marrow Transplant. 1996 Apr;17(4):517-25.

PMID:
8722348
47.

Gene therapy--the challenge for the future.

Moore MA, Leonard JP, Flasshove M, Bertino J, Gallardo H, Sadelain M.

Ann Oncol. 1996;7 Suppl 2:53-8. No abstract available.

PMID:
8805950
48.

Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant.

Flasshove M, Banerjee D, Bertino JR, Moore MA.

Leukemia. 1995 Oct;9 Suppl 1:S34-7.

PMID:
7475310
49.
50.

Pulmonary and cerebral irradiation for hyperleukocytosis in acute myelomonocytic leukemia.

Flasshove M, Schuette J, Sauerwein W, Hoeffken K, Seeber S.

Leukemia. 1994 Oct;8(10):1792. No abstract available.

PMID:
7934178

Supplemental Content

Loading ...
Support Center